Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Apilimod · LAM-002A, STA-5326

Small molecule · Inhibitor of PIKfyve (phosphatidylinositol-3-phosphate 5-kinase) (PIKFYVE) · developed by IRulya Therapeutics

Phase 2 Most advanced trial (none active)

IRLA Developer

2 Registered trials

What is Apilimod?

Apilimod is an oral small-molecule inhibitor of the lipid kinase PIKfyve, supplied as apilimod dimesylate capsules. By inhibiting PIKfyve it disrupts PIKfyve-mediated signaling and suppresses Toll-like receptor-induced production of IL-12 and IL-23. It is being studied in COVID-19 and amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LAM-002A, STA-5326
Drug type: Small molecule
Targets: PIKfyve (phosphatidylinositol-3-phosphate 5-kinase) (PIKFYVE)
Mechanism: Inhibitor of PIKfyve (phosphatidylinositol-3-phosphate 5-kinase) (PIKFYVE)
Pathways: TLR signaling, IL-12/IL-23 cytokine production, tumor cell migration, proliferation and survival
Therapy area: Infectious disease, Neurology
Developer: IRulya Therapeutics Inc. (IRLA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: GFW2K84S4L

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05163886	Phase 2	Amyotrophic Lateral Sclerosis	Completed	IRLA
NCT04446377	Phase 2	COVID-19 Disease	Completed	IRLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ALSAmyotrophic Lateral SclerosisCOVID-19 Disease

More from IRulya Therapeutics

LAM-001 Phase 2 LAM-003 Phase 1

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IRLA page.

Follow IRLA, the company behind Apilimod

See IRLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRLA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z